New Year Bumper Sale @ Rs. 1 X
Cilacar C 10/6.25 Tablet is a commercial drug that is prescribed in the form of Tablet. Other than this, Cilacar C 10/6.25 Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Cilacar C 10/6.25 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
The side effects typically associated with Cilacar C 10/6.25 Tablet include Loss of appetite, Gastric Irritation, Impotence. Apart from the aforementioned side effects, Cilacar C 10/6.25 Tablet can also lead to other problems, which have been listed below. These side effects of Cilacar C 10/6.25 Tablet are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Cilacar C 10/6.25 Tablet is Mild for pregnant women and Mild for women who are breastfeeding. Warnings related to Cilacar C 10/6.25 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Cilacar C 10/6.25 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Low Blood Pressure (Hypotension), Liver Disease, Kidney Disease are examples of such conditions. The section on Cilacar C 10/6.25 Tablet contraindications lists all such conditions.
Besides this, Cilacar C 10/6.25 Tablet may also have severe interaction with some medicines. A complete list of these interactions is given below.
In addition to the above precautions for Cilacar C 10/6.25 Tablet, it is important to know that it is not safe while driving, and is not habit-forming.
Cilacar C 10/6.25 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Cilacar C 10/6.25 Tablet safe for pregnant women?
Cilacar C has mild to no side effects in pregnant women.
Is the use of Cilacar C 10/6.25 Tablet safe during breastfeeding?
Side effects of Cilacar C for breastfeeding are little to none, so you can take it without doctor's advice.
What is the effect of Cilacar C 10/6.25 Tablet on the Kidneys?
Cilacar C has very mild side effects on the kidneys.
What is the effect of Cilacar C 10/6.25 Tablet on the Liver?
Very few cases of side effects of Cilacar C on the liver have been reported.
What is the effect of Cilacar C 10/6.25 Tablet on the Heart?
Side effects of Cilacar C rarely affect the heart.
Cilacar C 10/6.25 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Cilacar C 10/6.25 Tablet unless your doctor advises you to do so -
Is this Cilacar C 10/6.25 Tablet habit forming or addictive?
No, you will not get addicted to Cilacar C 10/6.25 Tablet.
Interaction between Food and Cilacar C 10/6.25 Tablet
Cilacar C 10/6.25 Tablet may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Cilacar C 10/6.25 Tablet
Taking Cilacar C 10/6.25 Tablet with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Thalitone ® (chlorthalidone)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 583-584
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448